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S U M M A R Y
Background: There are no available studies on the duration and risk factors of vancomycin-resistant
enterococci (VRE) carriage after hospital discharge. In this study we investigated the duration of
colonization with VRE and the risk factors for prolonged carriage in the outpatient clinic after discharge
from the hospital.
Methods: The study took place from January 2008 to September 2009. Patients were included if they
were identiﬁed as persistent VRE carriers by follow-up rectal swab or stool cultures in the outpatient
setting, after discharge from the hospital without clearance of VRE. The probability of culture positivity
and clearance was analyzed from the discharge date. Cox regression was performed to determine the risk
factors for prolonged carriage. VRE clearance was deﬁned as VRE-negative rectal (or stool) cultures on at
least three consecutive occasions a minimum of 1 week apart.
Results: One hundred twenty-seven patients were included in this study. Follow-up cultures were
conducted for a median of 8.86 weeks (range 1–90 weeks) after hospital discharge. The median duration
of culture positivity of VRE was 5.57 weeks (range 0–50.14 weeks). Ninety-six out of 127 patients (75.6%)
showed the ﬁrst negative culture result at a median time of 4.86 weeks (range 0–66 weeks) after
discharge. Among these patients, 15 were lost to follow-up after the ﬁrst negative culture and eight were
lost after the second negative culture. Sixty-eight patients (53.5%) were conﬁrmed to have clearance of
VRE during follow-up in the outpatient clinic. The median time to clearance after discharge was 8.86
weeks (range 2–90 weeks). In the cleared cases, the median time to the ﬁrst negative VRE culture result
was 4.71 weeks (range 0–66 weeks). Ninety percent of patients showed the ﬁrst negative culture result
at 25 weeks and VRE clearance at 30 weeks after discharge. Surgery or antibiotic use during admission
(p = 0.048 and p = 0.001, respectively), dialysis (p = 0.046), and discharge to a nursing home or other
health care institution (p = 0.025) were independently associated with prolonged colonization with VRE.
Conclusions: The median duration of VRE colonization was 5.57 weeks after hospital discharge. In the
cases with clearance during follow-up, the median time to clearance after discharge was 8.86 weeks. Risk
factors for prolonged carriage were surgery, antibiotic use during admission, dialysis, and discharge to a
nursing home or other health care institution. Therefore, patients with these risk factors should be
managed more carefully to prevent transmission of VRE in the outpatient clinic.
 2012 Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
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Although vancomycin-resistant enterococci (VRE) are consid-
ered to be low virulence pathogens, they are a common cause of
health care-associated infections.1 The National Healthcare Safety
Network (NHSN, which includes the former National Nosocomial
Infections Surveillance System) in the USA reported that <5% of* Corresponding author. Tel.: +82 2 3410 0322; fax: +82 2 3410 0041.
E-mail address: krpeck@skku.edu (K.R. Peck).
1201-9712/$36.00 – see front matter  2012 Published by Elsevier Ltd on behalf of In
http://dx.doi.org/10.1016/j.ijid.2012.09.019nosocomial enterococcal isolates were resistant to vancomycin in
1990, while resistance had increased to 33.3% in 2006–2007.1,2
Nationwide surveillance in Korea has also shown increasing
resistance of Enterococcus to vancomycin, ranging from 2.9% in
1997 to 17–21% in 2007.3,4 VRE infections are associated with
increased morbidity, mortality, and health care costs,5 and
immunocompromised or critically ill patients are at risk of severe
VRE infection.6
Because colonization with VRE may serve as a reservoir for the
transmission of VRE to other patients, routine screening cultures to
identify and isolate VRE carriers have been used to prevent furtherternational Society for Infectious Diseases.
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know the duration of colonization and the risk factors for
prolonged carriage. One of the causes of the spread of VRE in
hospitals is unrecognized ‘silent’ and prolonged fecal carriage.9
VRE can survive in the environment for prolonged periods (>1
week)10 and can be passed from one patient to another by health
care workers, even in the outpatient clinic. Generally, health care
providers do not take precautions against VRE colonizers once a
patient has been released from the hospital. However, VRE carriers,
especially those who have risk factors for prolonged carriage, may
need to be examined with caution, even in the outpatient clinic,
because identiﬁcation of VRE carriers and implementation of
contact precautions have been shown to be cost-effective and may
reduce VRE-related morbidity and mortality in high-risk popula-
tions for VRE acquisition among inpatients.11–14 Thus, the
assessment of the natural history and risk factors is needed to
inform infection control interventions.
Risk factors associated with increased VRE colonization include
the presence of immunosuppression or a serious comorbid
condition, increased length of hospital stay, residence in a long-
term care facility, proximity to another colonized or infected
patient or hospitalization in a room previously occupied by a
patient colonized with VRE, invasive procedures, and the
administration of broad-spectrum antibiotics or vancomycin.15,16
Previous studies on the natural history and risk factors for VRE
have been conducted among hospitalized patients.17–19 However,
the duration of colonization and factors related to decreasing the
likelihood of clearing VRE have not been established in the
outpatient setting. Although some VRE carriers in previous reports
had been readmitted after discharge, there have been no studies
concerning the outcome of VRE among outpatients. The objectives
of this study were to analyze the risk factors for prolonged VRE
carriage and the natural history of VRE after hospital discharge in
the outpatient clinic.
2. Methods
2.1. Study design and patients
A single-center retrospective cohort study was conducted from
January 2008 to September 2009 at a tertiary care hospital in Seoul,
Korea. Surveillance rectal cultures and genotypic analyses were
undertaken in inpatients thought to be at risk for VRE because of
prolonged hospitalization, antibiotic use, referral from another
health care facility, intensive care unit (ICU) stay, receiving a
transplant, or proximity to other patients with VRE. Patients who
grew VRE were isolated and sequential VRE cultures were
performed every week.
Among the cohort without VRE clearance before discharge, the
patients from whom VRE follow-up cultures (rectal swab or stool)
were performed in the outpatient clinic were included in this
study. The medical records were reviewed from the date of initial
VRE isolation until clearance of colonization or until loss to follow-
up in the outpatient clinic. The following information was
collected: referral from a long-term care facility, admission to
an acute care facility, primary diagnoses, dates of admission and
discharge, age at admission, sex, immunodeﬁciency status,
underlying diseases and severity as deﬁned by the McCabe and
Jackson scores, prognosis by the Charlson comorbidity index,
performance at discharge (independent/limited assistance or
extensive/total dependence), antimicrobial use and duration in
the inpatient and outpatient settings, acquisition of other
antibiotic-resistant bacteria, hospitalization in the ICU, presence
of any skin breaks, placement of a central venous catheter,
indwelling Foley catheter, feeding tube, or tracheostomy, any
surgery or invasive procedures during admission, time sincedischarge from the hospital, and destination after discharge (home
or other health care institution). Rectal samples were taken by
nurses in the inpatient setting; in the outpatient setting, stool
samples were collected by family members or a rectal swab was
taken by a home care nurse. The collected specimens were
processed on the day they were obtained, or were otherwise kept
refrigerated.
2.2. VRE cultures and genotyping
To isolate VRE, clinical specimens were inoculated on 5% sheep
blood agar and incubated for 48 h at 35 8C in a 5% CO2 atmosphere.
Rectal swabs or stools were inoculated on Enterococcosel culture
plates (Difco Laboratories, Detroit, MI, USA) containing 15 mg/ml
vancomycin and 8 mg/ml clindamycin at 35 8C in ambient air for
48 h. Presumptive Enterococcus species were identiﬁed by conven-
tional biochemical methods, including chromogenic agar for VRE
screening (bioMe´rieux, Marcy l’Etoile, France) and the Vitek 2 GP
card (bioMe´rieux).
vanA and vanB genotypes were determined from the ﬁrst
surveillance isolates. The genotype for glycopeptide resistance was
determined by multiplex PCR method, as described previously:20
enterococci were ﬁrst grown overnight at 37 8C in Todd–Hewitt
broth, and then 1-ml volumes were microcentrifuged and the
pellet was resuspended in 200 ml of TE buffer (10 mM Tris–HCl,
1 mM ethylenediaminetetraacetic acid (EDTA; pH 8.0)). The
suspensions were heated at 95 8C for 20 min and then micro-
centrifuged for 2 min. Five-microliter volumes of the supernatant
were subjected to PCR ampliﬁcation in 50-ml reaction mixtures
containing each deoxynucleoside triphosphate at a concentration
of 200 mM, each primer at a concentration of approximately 1 mM,
and 1 U of Taq polymerase (Boehringer Mannheim) in 10 mM Tris–
HCl (pH 8.3)–50 mM KCl–2 mM MgCl2–0.1% gelatin–0.1% Tween
20–0.1% Nonidet P-40. The samples were subjected to 35 PCR
cycles, each consisting of 1 min of denaturation at 94 8C, 2 min of
annealing at 60 8C, and 2 min of elongation at 72 8C. PCR products
were analyzed by electrophoresis on 2% agarose gels and were
stained with ethidium bromide. The oligonucleotide primers used
for the detection of vanA, vanB, vanC1, and vanC2 or vanC3
sequences were designed with reference to the sequences
deposited in GenBank under accession numbers X56895,
L06138, M75132, L29638, and L29639, respectively. Two PCR
reactions were set up for each sample. One contained primers
VanABF, VanAR, and VanBR, which direct ampliﬁcation of 231- and
330-bp fragments from the vanA and vanB genes, respectively. The
other contained primers VanC1F, VanC1R, VanC23F, and VanC23R,
which direct ampliﬁcation of 447- and 597-bp fragments from the
vanC1 gene and either the vanC2 or the vanC3 gene, respectively.
Multiplex PCRs were tested in duplicate. Known positive and
negative controls were also included with each PCR run. Genotype-
negative VRE isolates for which vancomycin minimum inhibitory
concentrations (MICs) were 4 mg/ml or higher, were also tested for
the presence of vanD using previously described primers.21
2.3. Deﬁnitions
Clearance of VRE colonization was deﬁned as VRE-negative
rectal (or stool) cultures on at least three consecutive occasions 1
week or longer apart in the outpatient setting.22 A positive VRE
culture result within 48 h after admission was considered as
acquisition of VRE outside of the study hospital. Otherwise,
patients were classiﬁed as having acquired the VRE in the study
hospital. Drug-resistant pathogens included methicillin-resistant
Staphylococcus aureus (MRSA), Gram-negative bacilli susceptible
only to a single class of antibiotics or resistant to all antibiotics
tested, and extended-spectrum beta-lactamase (ESBL) producers.
Figure 1. Number of patients in the study.
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The duration of VRE culture-positivity after discharge was
calculated. Because positive VRE cultures were observed after one
or two consecutive negative cultures and the positive follow-up
intervals were more regular than negative follow-up intervals, an
event was deﬁned as the last positive VRE culture rather than
clearance in the outpatient clinic. The date of discharge was used as
the observation starting point. Risk factors associated with
prolonged VRE carriage in the outpatient clinic were determined
by comparing survival curves and multiple regression. Finally, the
time to clearance and ﬁrst negative VRE in the cleared cases were
estimated using the Kaplan–Meier method.
2.5. Statistical analyses
Patients were censored at the time of readmission or at loss to
follow-up. The time-to-event analysis in weeks between discharge
date and the last positive VRE was done using Kaplan–Meier
methods. The comparison of curves for selected characteristics was
conducted using log rank tests. Risk factors for prolonged carriage
were evaluated using a Cox proportional hazard regression model
in which the variables suggested by the univariate analysis
(p < 0.1) or thought to be relevant were included. Additionally, a
forward stepwise multiple regression was performed using all
available variables with considered interactions. For all analyses, a
type I error rate of 0.05 was used. The statistical analysis was
performed using SPSS v.17 software (SPSS, Chicago, IL, USA).
3. Results
3.1. Characteristics of the patients
This study included 127 VRE carriers without clearance before
discharge. Their mean age was 58.9 years; 60.5% (n = 78) were
male, 37.0% (n = 47) had a malignancy, and 45.7% (n = 58) had been
transferred from another institution. The median follow-up testing
interval was 2.2 weeks (range 0–18 weeks) and the mean overall
test frequency was 5.1  4. All the species were Enterococcus faecium
(Table 1). The number of study participants is shown in Figure 1
(Figures 2 and 3).Table 1
Characteristics of the 127 patients included in the study
Characteristic n (%)
Age, years, mean  SD 58.9  14.4
Male sex, n (%) 78 (61.4)
Underlying disease, n (%)
Malignancy 47 (37.0)
Solid organ transplant 18 (14.2)
Diabetes 26 (20.5)
Cardiovascular 17 (13.4)
Cirrhosis 13 (10.2)
Dialysis 7 (5.5)
Othera 36 (28.3)
Hospital stay, days, median (range) 17 (2–108)
Transferred from other hospitals, n (%) 58 (45.7)
VRE acquisition from another hospital, n (%) 45 (35.4)
Enterococcus faecium, n (%) 127 (100)
Genotype, n (%)
vanA 79 (62.2)
Not done 48 (37.8)
Testing interval at outpatient clinic, weeks, median (range) 2.2 (0–18)
Test frequency at OPD, mean  SD 5.1  4
SD, standard deviation; OPD, outpatient department.
a Includes connective tissue, chronic pulmonary, neurologic, and gastrointestinal
disorders and major traumas.3.2. Duration of colonization after discharge
The median duration of follow-up after discharge was 8.86
weeks (range 1–90 weeks). The median duration of culture
positivity was estimated at 5.57 weeks (range 0–50.14 weeks)
(Figure 2). Ninety-six patients (75.6%) showed the ﬁrst negative
culture results after a median of 4.86 weeks (range 0–66 weeks).
Fifteen patients were lost to follow-up after the ﬁrst negative
culture and eight were censored after the second negative culture.
After one negative follow-up culture, the next was negative in
93.8% (n = 76/81) of patients. After two negative cultures, 93.2%
(n = 68/73) remained culture-negative. Sixty-eight (53.5%) out of
127 patients were conﬁrmed for VRE clearance in the outpatient
clinic. Others were readmitted or lost to follow-up before
clearance. Two patients subsequently turned positive after initially
meeting the criteria for VRE clearance. The median time to
clearance after discharge was 8.86 weeks (range 2–90) (Figure 4).
Eighty percent of these 68 patients were cleared of VRE in 17 weeks
and 90% in 30 weeks after discharge. In the cleared cases, the
median time to the ﬁrst negative VRE culture result was 4.71
weeks (range 0–66) (Figure 5). Ninety percent of patients received
the ﬁrst negative culture results 25 weeks after discharge and 80%
of patients at 11 weeks.Figure 2. Kaplan–Meier estimate of the duration of positive VRE culture after
discharge.
Figure 3. Duration of positive VRE culture after discharge: relationship to (A)
antibiotic use during admission, and (B) dialysis.
Figure 4. Kaplan–Meier estimate of time until VRE clearance after discharge.
Figure 5. Kaplan–Meier estimate of time until ﬁrst negative VRE in the cleared
cases.
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Log rank tests revealed that variables associated with prolonged
VRE carriage were ﬂuoroquinolone use during admission (p = 0.048),
patient discharge to another institution (p = 0.038), dialysis
(p = 0.034), immunosuppression in the outpatient clinic
(p = 0.002), and antibiotic use during admission (p = 0.001). Four
factors were signiﬁcantly associated with prolonged VRE carriage by
Cox proportional hazard model: surgery or antibiotic use during
admission (p = 0.048 and p = 0.001, respectively), dialysis (p = 0.046),
and patient discharge to another health care institution (p = 0.025)
(Table 2, Figures 2 and 3). The subgroup analysis of antibiotic use
during admission revealed that only ﬂuoroquinolone use was a
signiﬁcant risk factor for prolonged VRE carriage after discharge.
4. Discussion
This is the ﬁrst study to show the natural history and risk factors
for prolonged carriage of VRE in the outpatient clinic. Although
previous study populations have included some outpatients,18
there have been no reports to help clinicians manage VRE carriers
after hospital discharge.
Risk factors for the acquisition of VRE include proximity to non-
isolated VRE cases, colonization pressure, history of major trauma,
use of antimicrobials (especially treatment with metronidazole,
vancomycin, cephalosporin, ﬂuoroquinolone, anti-anaerobe or
multiple and prolonged courses of antimicrobials), previous
hospitalization, management in an ICU, prior exposure to an acute
care facility, intra-hospital transfer between ﬂoors, prolonged
hospital stay, severe illness (especially end-stage renal disease
requiring dialysis, cancer, transplant recipient), old age, female
gender, diabetes, installation of a urinary catheter, elevated serum
creatinine or low serum albumin level, invasive devices, enteral
feeding, being a resident of a long-term care facility, and the
presence of a decubitus ulcer.10,23–35 Factors associated with
prolongation of colonization are receipt of antimicrobial therapy,
admission to an acute care facility, prolonged duration of
hospitalization and intensive care or prolonged stay in a long-
term care facility, and a moderate-to-severe level of dependen-
cy.18,19,35,36 These data were primarily obtained from inpatient
settings. These risk factors for the acquisition and prolonged
carriage of VRE were used for analysis in this study. Factors that
may have contributed to prolonged colonization with VRE in this
Table 2
Variables associated with prolonged carriage of vancomycin-resistant enterococci
Variable N = 127, n (%) Log rank p-value Cox proportional hazard model
HR (95% CI) p-Value
Male 78 (60.5) 0.850
Age >60 years 61 (48.0) 0.257
History of admission in prior 12 months 110 (86.6) 0.759
Admission via ER 54 (42.5) 0.141
Hospital stay >30 days 38 (29.9) 0.948
Readmission 41 (32.3) 0.721
Surgery during admission 55 (43.3) 0.346 1.75 (1.01–3.05) 0.048
Dialysis 6 (4.7) 0.034 7.62 (1.03–56.21) 0.046
Invasive procedure during admission 41 (32.3) 0.639
Immunosuppression (admission) 33 (26.0) 0.093 1.12 (0.49–2.57) 0.788
Immunosuppression (OPD) 40 (31.5) 0.002 0.64 (0.31–1.33) 0.230
Acquisition of drug-resistant pathogen 37 (29.1) 0.627
CVC during admission 59 (46.5) 0.326
ICU care 40 (31.5) 0.886
Antibiotic use during admission 104 (81.9) 0.001 3.60 (1.68–7.74) 0.001
Vancomycin 29 (27.9a) 0.259 0.794b
Cephalosporin 80 (76.9a) 0.564 0.390b
b-Lactam/b-lactamase inhibitor 85 (81.7a) 0.663 0.893b
Metronidazole 16 (15.4a) 0.303 0.151b
Carbapenem 24 (23.1a) 0.360 0.639b
Fluoroquinolone 27 (26.0a) 0.048 2.15 (1.10–4.23) 0.026b
Aminoglycoside 14 (13.5a) 0.866 0.890b
Antibiotic use in OPD 50 (39.4) 0.070 1.37 (0.73–2.55) 0.327
Antibiotics duration >20 days (admission) 37 (29.1) 0.113
Antibiotic duration >14 days (OPD) 26 (20.5) 0.218
ICU care >7 days 21 (16.5) 0.504
Rapidly or ultimately fatal underlying diseases by McCabe 49 (38.6) 0.280
Charlson comorbidity score >4 49 (38.6) 0.364
Discharged to LTCF or other institution 11 (8.7) 0.038 5.28 (1.23–22.70) 0.025
VRE acquisition from another hospital 45 (35.4) 0.877
HR, hazard ratio; CI, conﬁdence interval; ER, emergency room; OPD, outpatient department; CVC, central venous catheter; ICU, intensive care unit; LTCF, long-term-care
facility; VRE, vancomycin-resistant enterococci.
a Percentage derived from the number of patients given antibiotics during admission.
b Subgroup analysis from the factor ‘antibiotic use during admission’.
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dialysis, and patient destination after discharge. Compared with
previous studies, prior admission to an acute care facility,
duration of hospital stay, and performance at discharge were
not signiﬁcant risk factors in this study. This may reﬂect the fact
that the duration of culture-positivity was not estimated from the
initial culture-positive date but from the discharge date, and
because the performance at the time of hospital discharge was not
described in detail. In this study, antimicrobial use during
admission was one of the risk factors, but not antimicrobial use
in the outpatient clinic. There might be confounding variables;
underlying diseases and immunosuppression need to be consid-
ered together with antibiotic use. For instance, solid organ
transplant recipients take a prolonged prophylaxis for Pneumo-
cystis pneumonia. In Korea, it is impossible to obtain antibiotics
without a doctor’s prescription. Considering that most patients
who were not censored had complex diseases and took antibiotics
provided by our hospital, there is little chance that the study
patients took other antibiotics without our knowledge. In
addition, admission to the ICU was not a signiﬁcant risk factor
for prolonged carriage in this study, unlike previous reports. This
may result from patients having stayed in the ICU for only 1–2
days after surgery without any apparent reasons for intensive
care. However, prolonged ICU admission (> 7 days) was not
signiﬁcant either.
Although the time out of the hospital has been found to be
inversely related to the likelihood that a patient would be
colonized on readmission,17,18 this study did not show a shorter
positive duration compared with other reports that have included
inpatients. In this study, VRE persisted for a median of 5.57 weeks
(range 0–50.14 weeks), with one patient being colonized for thewhole 90-week study period. This is similar to a report describing
VRE colonization for a median of 7 weeks and for up to 19
months.17 In a long-term care facility, VRE colonization has been
shown to persist for up to 6 months with a median duration of
colonization of 67 days.36 Other studies have demonstrated
persistent colonization for up to 709 days, 12 months, and even
up to 3 years.18,37 However, in the present study, the median time
was not estimated from the initial positive culture but from
hospital discharge. Thus, the results should be interpreted with
caution. Time to the last positive culture was analyzed in this study
because the duration of the interval to the next culture was a
signiﬁcant predictor of the next follow-up culture result.18
Time to clearance was deﬁned in this study as in other
studies:17,18,36 clearance was at least three consecutive negative
cultures 1 week or longer apart,8 although it was deﬁned as two
consecutive negative cultures in one study.36 The median time to
VRE clearance was 8.86 weeks (range 2–90 weeks). However, VRE
carriers were not sampled at regular intervals. If regular testing
had been performed after hospital discharge, negative culture
results would have been detected more rapidly in some patients.
Therefore, the median time to clearance may have been over-
estimated in this study. On the other hand, because the time to
clearance was calculated in only 68 out of 127 patients, the true
prolonged colonized patients might have been excluded and the
median time to clearance could be an underestimate.
In one study the sensitivity of a single stool or rectal swab was
determined to be 79% and the cumulative sensitivity would be
99.1% for detecting VRE with three cultures.38 In another report,
the sensitivity of the rectal swab culture was 58% (100% at high
densities to 0% at low densities).39 One study reported that 92% of
patients with a ﬁrst negative follow-up culture were negative at
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negative for a third culture after two consecutive negative cultures,
and 95% of patients were negative for a fourth culture after three
sequential negative cultures.18 In another study, the percentages of
negative cultures after one, two, and three negative cultures were
52%, 68%, and 72%, respectively.40 In this study, after one negative
follow-up culture, the next was negative in 93.8% (n = 76/81) of the
patients, and after two negative cultures, 93.2% (n = 68/73)
remained culture-negative. Long follow-up testing intervals and
the techniques used to obtain the specimens may explain this
relatively high negative follow-up culture rate. Two patients were
culture-positive after three consecutive negative cultures (cleared
cases) in this study. In a recent study, two of six chronic
hemodialysis patients and 10 of 36 non-hemodialysis patients
were culture-positive again after three consecutive negative
cultures.41 Therefore it may be necessary to monitor previously
colonized, high-risk patients for the reemergence of VRE. The false-
negative rate of rectal swab cultures may also contribute to the
increasing prevalence of VRE.39
Since 2005, the government of Korea has gradually been
banning antibiotic feed additives. Antibiotic consumption per ton
of meat was 0.44 kg in 2009. This was higher than in Japan,
Denmark, and the USA. There has been a study to assess the
possibility of VRE transmission from animals to humans in Korea.42
The authors analyzed 150 specimens from farm animals, 15 raw
chicken meat samples, and stools from 200 healthy people for
Enterococcus. The prevalence of VRE was 14.7% (22/150) in farm
animal specimens, 60% (9/15) in raw chicken meat, and 1% (2/200)
in healthy people. One of 22 animal VRE isolates and all of the nine
raw chicken VRE isolates were vanA E. faecium. This study
suggested that there was little evidence of VRE transmission from
animals to healthy people despite the high recovery of VRE in farm
animal specimens and raw chicken meat.
In Korea, VRE screening in the outpatient setting is not standard
clinical practice. However, we should screen for rectal VRE when
non-cleared VRE carriers are readmitted. We practiced this in the
outpatient clinic and the National Health Insurance of Korea
reimburses the expense.
This study has additional limitations. First, the study population
was relatively small and a large proportion of patients (46.5%, 59/
127) were censored. Second, clinical information and culture
results were collected retrospectively. Therefore, the follow-up
intervals were too heterogeneous. To solve this problem, time to
clearance using the last positive culture was evaluated as a ﬁnal
event for the statistical analysis, as well as clearance. Third, we
could not assess the duration of colonization with regard to
whether the VRE was the same strain or a new acquisition,
although it is possible that the duration of colonization was
prolonged because of newly acquired VRE from another health care
institution or nursing home.
Despite the weaknesses of this study, the results may inform
clinicians in caring for VRE carriers in the outpatient clinic and
raise awareness of health care providers to VRE transmission after
hospital discharge.
In conclusion, this study showed the median duration of VRE
colonization to be 5.57 weeks after hospital discharge. For the
cleared cases during follow-up, the median time to clearance after
discharge was 8.86 weeks. The risk factors for prolonged carriage
were surgery, antibiotic use during admission, dialysis, and
discharge to a nursing home or other health care institution.
Patients with these risk factors should be managed more carefully
to prevent the transmission of VRE in the outpatient clinic. Further
large prospective studies are needed to deﬁne the accurate
assessment of VRE carriage and risk factors for prolonged
colonization in the outpatient clinic.
Conﬂict of interest: No conﬂict of interest to declare.References
1. National Nosocomial Infections Surveillance (NNIS) System Report, data sum-
mary from January 1992 through June 2004, issued October 2004. Am J Infect
Control 2004;32:470–85.
2. Hidron AI, Edwards JR, Patel J, Horan TC, Sievert DM, Pollock DA, Fridkin SK.
NHSN annual update: antimicrobial-resistant pathogens associated with
healthcare-associated infections: annual summary of data reported to the
National Healthcare Safety Network at the Centers for Disease Control and
Prevention, 2006–2007. Infect Control Hosp Epidemiol 2008;29:996–1011.
3. Lee K, Lee MA, Lee CH, Lee J, Roh KH, Kim S, et al. Increase of ceftazidime- and
ﬂuoroquinolone-resistant Klebsiella pneumoniae and imipenem-resistant Aci-
netobacter spp. in Korea: analysis of KONSAR study data from 2005 and 2007.
Yonsei Med J 2010;51:901–11.
4. Lee K, Jang SJ, Lee HJ, Ryoo N, Kim M, Hong SG, Chong Y. Increasing prevalence of
vancomycin-resistant Enterococcus faecium, expanded-spectrum cephalospo-
rin-resistant Klebsiella pneumoniae, and imipenem-resistant Pseudomonas aer-
uginosa in Korea: KONSAR study in 2001. J Korean Med Sci 2004;19:8–14.
5. Song X, Srinivasan A, Plaut D, Perl TM. Effect of nosocomial vancomycin-
resistant enterococcal bacteremia on mortality, length of stay, and costs. Infect
Control Hosp Epidemiol 2003;24:251–6.
6. Patel R. Clinical impact of vancomycin-resistant enterococci. J Antimicrob Che-
mother 2003;51(Suppl 3):iii13–21.
7. Muto CA, Jernigan JA, Ostrowsky BE, Richet HM, Jarvis WR, Boyce JM, Farr BM.
SHEA guideline for preventing nosocomial transmission of multidrug-resistant
strains of Staphylococcus aureus and Enterococcus. Infect Control Hosp Epidemiol
2003;24:362–86.
8. Centers for Disease Control and Prevention (CDC). Recommendations for pre-
venting the spread of vancomycin resistance. Recommendations of the Hospital
Infection Control Practices Advisory Committee (HICPAC). MMWR Recomm Rep
1995;44:1–13.
9. Martone WJ. Spread of vancomycin-resistant enterococci: why did it happen in
the United States? Infect Control Hosp Epidemiol 1998;19:539–45.
10. Zirakzadeh A, Patel R. Vancomycin-resistant enterococci: colonization, infec-
tion, detection, and treatment. Mayo Clin Proc 2006;81:529–36.
11. Muto CA, Giannetta ET, Durbin LJ, Simonton BM, Farr BM. Cost-effectiveness of
perirectal surveillance cultures for controlling vancomycin-resistant Entero-
coccus. Infect Control Hosp Epidemiol 2002;23:429–35.
12. Puzniak LA, Gillespie KN, Leet T, Kollef M, Mundy LM. A cost–beneﬁt analysis of
gown use in controlling vancomycin-resistant Enterococcus transmission: is it
worth the price? Infect Control Hosp Epidemiol 2004;25:418–24.
13. Price CS, Paule S, Noskin GA, Peterson LR. Active surveillance reduces the
incidence of vancomycin-resistant enterococcal bacteremia. Clin Infect Dis
2003;37:921–8.
14. Mayhall CG. Control of vancomycin-resistant enterococci: it is important, it is
possible, and it is cost-effective. Infect Control Hosp Epidemiol 2002;23:
420–3.
15. Vergis EN, Hayden MK, Chow JW, Snydman DR, Zervos MJ, Linden PK, et al.
Determinants of vancomycin resistance and mortality rates in enterococcal
bacteremia. A prospective multicenter study. Ann Intern Med 2001;135:
484–92.
16. Furtado GH, Mendes RE, Pignatari AC, Wey SB, Medeiros EA. Risk factors for
vancomycin-resistant Enterococcus faecalis bacteremia in hospitalized patients:
an analysis of two case–control studies. Am J Infect Control 2006;34:447–51.
17. Montecalvo MA, de Lencastre H, Carraher M, Gedris C, Chung M, VanHorn K,
Wormser GP. Natural history of colonization with vancomycin-resistant En-
terococcus faecium. Infect Control Hosp Epidemiol 1995;16:680–5.
18. Byers KE, Anglim AM, Anneski CJ, Farr BM. Duration of colonization with
vancomycin-resistant Enterococcus. Infect Control Hosp Epidemiol
2002;23:207–11.
19. Pacio GA, Visintainer P, Maguire G, Wormser GP, Raffalli J, Montecalvo MA.
Natural history of colonization with vancomycin-resistant enterococci, methi-
cillin-resistant Staphylococcus aureus, and resistant Gram-negative bacilli
among long-term-care facility residents. Infect Control Hosp Epidemiol
2003;24:246–50.
20. Bell JM, Paton JC, Turnidge J. Emergence of vancomycin-resistant enterococci in
Australia: phenotypic and genotypic characteristics of isolates. J Clin Microbiol
1998;36:2187–90.
21. Perichon B, Reynolds P, Courvalin P. VanD-type glycopeptide-resistant Entero-
coccus faecium BM4339. Antimicrob Agents Chemother 1997;41:2016–8.
22. Recommendations for preventing the spread of vancomycin resistance. Recom-
mendations of the Hospital Infection Control Practices Advisory Committee
(HICPAC). MMWR Recomm Rep 1995;44:1–13.
23. Harbarth S, Cosgrove S, Carmeli Y. Effects of antibiotics on nosocomial epide-
miology of vancomycin-resistant enterococci. Antimicrob Agents Chemother
2002;46:1619–28.
24. Fridkin SK, Edwards JR, Courval JM, Hill H, Tenover FC, Lawton R, et al. The effect
of vancomycin and third-generation cephalosporins on prevalence of vanco-
mycin-resistant enterococci in 126 U.S. adult intensive care units. Ann Intern
Med 2001;135:175–83.
25. Elizaga ML, Weinstein RA, Hayden MK. Patients in long-term care facilities: a
reservoir for vancomycin-resistant enterococci. Clin Infect Dis 2002;34:441–6.
26. Bonten MJ, Slaughter S, Ambergen AW, Hayden MK, van Voorhis J, Nathan C,
Weinstein RA. The role of ‘‘colonization pressure’’ in the spread of vancomycin-
resistant enterococci: an important infection control variable. Arch Intern Med
1998;158:1127–32.
K.M. Sohn et al. / International Journal of Infectious Diseases 17 (2013) e240–e246e24627. Ostrowsky BE, Trick WE, Sohn AH, Quirk SB, Holt S, Carson LA, et al. Control of
vancomycin-resistant Enterococcus in health care facilities in a region. N Engl J
Med 2001;344:1427–33.
28. Rao GG, Ojo F, Kolokithas D. Vancomycin-resistant Gram-positive cocci: risk
factors for faecal carriage. J Hosp Infect 1997;35:63–9.
29. Yang KS, Fong YT, Lee HY, Kurup A, Koh TH, Koh D, Lim MK. Predictors of
vancomycin-resistant Enterococcus (VRE) carriage in the ﬁrst major VRE out-
break in Singapore. Ann Acad Med Singapore 2007;36:379–83.
30. Tornieporth NG, Roberts RB, John J, Hafner A, Riley LW. Risk factors associated
with vancomycin-resistant Enterococcus faecium infection or colonization in
145 matched case patients and control patients. Clin Infect Dis 1996;23:767–72.
31. Zhou Q, Moore C, Eden S, Tong A, McGeer A. Factors associated with acquisition
of vancomycin-resistant enterococci (VRE) in roommate contacts of patients
colonized or infected with VRE in a tertiary care hospital. Infect Control Hosp
Epidemiol 2008;29:398–403.
32. Askarian M, Afkhamzadeh R, Monabbati A, Daxboeck F, Assadian O. Risk factors
for rectal colonization with vancomycin-resistant enterococci in Shiraz, Iran. Int
J Infect Dis 2008;12:171–5.
33. Byers KE, Anglim AM, Anneski CJ, Germanson TP, Gold HS, Durbin LJ, et al. A
hospital epidemic of vancomycin-resistant Enterococcus: risk factors and
control. Infect Control Hosp Epidemiol 2001;22:140–7.
34. Song JY, Cheong HJ, Jo YM, Choi WS, Noh JY, Heo JY, et al. Vancomycin-resistant
Enterococcus colonization before admission to the intensive care unit: a
clinico-epidemiologic analysis. Am J Infect Control 2009;37:734–40.35. Benenson S, Cohen MJ, Block C, Stern S, Weiss Y, Moses AE. Vancomycin-
resistant enterococci in long-term care facilities. Infect Control Hosp Epidemiol
2009;30:786–9.
36. Brennen C, Wagener MM, Muder RR. Vancomycin-resistant Enterococcus fae-
cium in a long-term care facility. J Am Geriatr Soc 1998;46:157–60.
37. Boyce JM, Opal SM, Chow JW, Zervos MJ, Potter-Bynoe G, Sherman CB, et al.
Outbreak of multidrug-resistant Enterococcus faecium with transferable vanB
class vancomycin resistance. J Clin Microbiol 1994;32:1148–53.
38. Weinstein JW, Tallapragada S, Farrel P, Dembry LM. Comparison of rectal and
perirectal swabs for detection of colonization with vancomycin-resistant en-
terococci. J Clin Microbiol 1996;34:210–2.
39. D’Agata EM, Gautam S, Green WK, Tang YW. High rate of false-negative results
of the rectal swab culture method in detection of gastrointestinal colonization
with vancomycin-resistant enterococci. Clin Infect Dis 2002;34:167–72.
40. Huckabee CM, Huskins WC, Murray PR. Predicting clearance of colonization with
vancomycin-resistant enterococci and methicillin-resistant Staphylococcus aure-
us by use of weekly surveillance cultures. J Clin Microbiol 2009;47:1229–30.
41. Park I, Park RW, Lim SK, Lee W, Shin JS, Yu S, et al. Rectal culture screening for
vancomycin-resistant Enterococcus in chronic haemodialysis patients: false-
negative rates and duration of colonisation. J Hosp Infect 2011;79:147–50.
42. Song JY, Hwang IS, Eom JS, Cheong HJ, Bae WK, Park YH, et al. Prevalence and
molecular epidemiology of vancomycin-resistant enterococci (VRE) strains
isolated from animals and humans in Korea. Korean J Intern Med
2005;20:55–62.
